Foerster A, Simonsen S, Frøysaker T
Department of Pathology, National Hospital, Oslo, Norway.
APMIS. 1988 Jan;96(1):14-24.
A brief description is given of the most important morphological changes in endomyocardial biopsy specimens taken from cyclosporin A (CyA)-treated cardiac allograft recipients. The National Hospital of Norway was, in 1983, the first Scandinavian hospital to perform a heart transplantation, an event facilitated by the new immunosuppressive drug CyA. Up to now (February 1987), 38 allogeneic orthotopic transplants have been carried out on a total of 37 patients, of whom 32 are alive and clinically well. There was no operative mortality, but 5 patients died of other causes: Two early rejections, one arrhythmia due to moderate rejection, one Toxoplasma myocarditis and one early graft failure due to donor heart coronary artery disease. The observation time ranges from six weeks to 39 months. The first 9 patients received CyA and prednisolone; all subsequent recipients were treated with Azathioprine additionally. Thirty six grafts were controlled by 557 sequential biopsy procedures which yielded 2783 endomyocardial specimens for histopathological examination. A histological diagnosis of rejection was made 99 times in 32 grafts (mean 2,6). Twenty four biopsies were obtained on clinical indication in 15 patients, and rejection was diagnosed in 11 biopsies. Evaluation of endomyocardial biopsies is important in monitoring cardiac recipients and provides a morphological index of acute rejection. Serial biopsies with adequate endomyocardial sampling from different areas of the right ventricle make it possible to diagnose acute cellular rejection at an early stage and are essential to control immunosuppressive treatment. Endomyocardial biopsy is a safe and reliable procedure and plays an important role in the management of cardiac allograft rejection.
本文简要描述了从接受环孢素A(CyA)治疗的心脏移植受者获取的心肌内膜活检标本中最重要的形态学变化。挪威国家医院于1983年成为斯堪的纳维亚地区第一家进行心脏移植的医院,这一事件因新型免疫抑制药物CyA而得以推动。截至目前(1987年2月),已对37名患者进行了38例同种异体原位移植,其中32例存活且临床状况良好。手术无死亡病例,但有5例患者死于其他原因:2例早期排斥反应,1例因中度排斥反应导致心律失常,1例弓形虫心肌炎,1例因供体心脏冠状动脉疾病导致早期移植失败。观察时间为6周至39个月。前9例患者接受CyA和泼尼松龙治疗;所有后续受者还额外接受硫唑嘌呤治疗。通过557次连续活检程序对36例移植心脏进行了监测,共获取2783份心肌内膜标本用于组织病理学检查。32例移植心脏中有99次组织学诊断为排斥反应(平均2.6次)。15例患者根据临床指征进行了24次活检,其中11次活检诊断为排斥反应。心肌内膜活检评估对于监测心脏移植受者很重要,并提供了急性排斥反应的形态学指标。从右心室不同区域进行充分的心肌内膜采样的系列活检能够在早期诊断急性细胞排斥反应,对于控制免疫抑制治疗至关重要。心肌内膜活检是一种安全可靠的程序,在心脏移植排斥反应的管理中发挥着重要作用。